Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency
- PMID: 32909511
- DOI: 10.1177/0267659120957856
Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency
Abstract
Background: Contrast-induced nephropathy (CIN) has become a common cause of hospital-acquired acute kidney injury in elderly patients. Trimetazidine (TMZ) is a type of anti-ischemic drug developed in recent years, which can reduce the incidence of CIN. This study aimed to evaluate the efficacy of TMZ in the prevention of contrast-induced nephropathy in elderly patients with renal insufficiency undergoing percutaneous coronary intervention (PCI) and to explore the mechanism of action.
Methods: A total of 310 elderly patients with renal insufficiency undergoing elective PCI were enrolled and randomly assigned to a control group (n = 155, hydration only) and a TMZ group (n = 155, 20 mg thrice daily orally 24 hours before and 72 hours after PCI). The primary endpoint of the study was the incidence of CIN, which was defined as an increase of 25% or more, or an absolute increase of 0.5 mg/dL or more in serum creatinine from baseline value, at 48 to 72 hours following the exposure to contrast media (CM).
Results: The incidence of CIN was significantly lower in the TMZ group than that in the control group (3.2% vs. 9.7%, p = 0.021). There was no difference regarding the incidence of major adverse events during hospitalization between the TMZ group and control group (1.9% vs. 2.6%, p = 1.000). Binary logistic regression results showed that TMZ was protective factors of CIN (OR = 0.274; 95% CI: 0.089-0.847; p = 0.025).
Conclusion: Therefore, we came to the conclusion that prophylactic administration of TMZ can prevent the occurrence of CIN in elderly patients with renal insufficiency undergoing PCI and has a certain protective effect on the renal function of patients. According to the experimental results and the mechanism of TMZ on cardiomyocytes, we speculate that TMZ increases kidney glucose metabolism, reduces fatty acid oxidation, and also has a protective effect on kidney free radical damage and ischemia-reperfusion injury.
Keywords: contrast-induced nephropathy; percutaneous coronary intervention; prevention; renal insufficiency; trimetazidine.
Similar articles
-
Trimetazidine as an adjunct to standard hydration reduces the incidence of contrast-induced acute kidney injury in patients with renal insufficiency undergoing coronary angiography or percutaneous cardiac intervention: a systematic review and meta-analysis.BMC Nephrol. 2024 Dec 23;25(1):471. doi: 10.1186/s12882-024-03872-9. BMC Nephrol. 2024. PMID: 39716106 Free PMC article.
-
Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.Eur J Med Res. 2018 May 18;23(1):23. doi: 10.1186/s40001-018-0320-2. Eur J Med Res. 2018. PMID: 29776437 Free PMC article. Clinical Trial.
-
Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.Cardiovasc Revasc Med. 2017 Jul-Aug;18(5):315-319. doi: 10.1016/j.carrev.2017.02.006. Epub 2017 Feb 10. Cardiovasc Revasc Med. 2017. PMID: 28532702
-
Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).Medicine (Baltimore). 2021 Mar 12;100(10):e24603. doi: 10.1097/MD.0000000000024603. Medicine (Baltimore). 2021. PMID: 33725824 Free PMC article.
-
Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.Am J Cardiol. 2014 Aug 1;114(3):389-94. doi: 10.1016/j.amjcard.2014.04.052. Epub 2014 May 16. Am J Cardiol. 2014. PMID: 24927970 Clinical Trial.
Cited by
-
Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.BMC Nephrol. 2021 Jun 2;22(1):206. doi: 10.1186/s12882-021-02405-y. BMC Nephrol. 2021. PMID: 34078303 Free PMC article.
-
Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.Am J Cardiovasc Drugs. 2025 Jul;25(4):443-460. doi: 10.1007/s40256-025-00724-1. Epub 2025 Apr 3. Am J Cardiovasc Drugs. 2025. PMID: 40180780 Review.
-
Naringin, Trimetazidine and Baroreflex in Renal Ischemia-Reperfusion Injury.Arq Bras Cardiol. 2021 Aug;117(2):298-299. doi: 10.36660/abc.20210453. Arq Bras Cardiol. 2021. PMID: 34495222 Free PMC article. English, Portuguese. No abstract available.
-
Trimetazidine as an adjunct to standard hydration reduces the incidence of contrast-induced acute kidney injury in patients with renal insufficiency undergoing coronary angiography or percutaneous cardiac intervention: a systematic review and meta-analysis.BMC Nephrol. 2024 Dec 23;25(1):471. doi: 10.1186/s12882-024-03872-9. BMC Nephrol. 2024. PMID: 39716106 Free PMC article.
-
Effect of remote ischemic preconditioning, nicorandil, and trimetazidine in contrast-induced nephropathy: a network meta-analysis of randomized controlled trials.Ren Fail. 2024 Dec;46(2):2431141. doi: 10.1080/0886022X.2024.2431141. Epub 2024 Nov 27. Ren Fail. 2024. PMID: 39604217 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous